Piper Sandler has increased its price target for Quest Diagnostics (DGX) to $215 from $200, while maintaining a Neutral rating on the stock. This adjustment reflects a moderated outlook for the company’s valuation by the firm. The article also provides a brief overview of recent insider transactions and other analyst ratings for Quest Diagnostics.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Piper Sandler Adjusts Price Target on Quest Diagnostics to $215 From $200, Maintains Neutral Rating
Piper Sandler has increased its price target for Quest Diagnostics (DGX) to $215 from $200, while maintaining a Neutral rating on the stock. This adjustment reflects a moderated outlook for the company’s valuation by the firm. The article also provides a brief overview of recent insider transactions and other analyst ratings for Quest Diagnostics.